Crossmark

Plasma endostatin at intensive care admission is independently associated with acute kidney injury, dialysis, and mortality in COVID-19

Crossref DOI link: https://doi.org/10.1186/s40635-025-00748-6

Published Online: 2025-04-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Koozi, Hazem https://orcid.org/0000-0002-5892-3524
Engström, Jonas

Zwawi, Ahmad

Spångfors, Martin

Didriksson, Ingrid

Larsson, Anders

Friberg, Hans

Frigyesi, Attila
Funding

Funding for this research was provided by:

Centralsjukhuset Kristianstad

Regional research support, Region Skåne (2022-1284)

Government funding of clinical research within the Swedish National Health Service (2022:YF0009 and 2022-0075)

Crafoordska Stiftelsen (2021-0833)

Lions Skåne research grants

Skånes universitetssjukhus

Hjärt-Lungfonden (2022-0352, 2022-0458)

Regional research support, Region Skåne

Government funding of clinical research within the Swedish National Health Service (2022-0226, 2021-10233)

Hans-Gabriel och Alice Trolle-Wachtmeisters stiftelse för medicinsk forskning

Lund University
License Information

Text and Data Mining valid from 2025-04-03

Version of Record valid from 2025-04-03
More Information

Article History

Received: 19 December 2024

Accepted: 10 March 2025

First Online: 3 April 2025

Declarations

:

: The study protocol was approved by the Swedish Ethical Review Authority (Dnr 2020-011955). Written informed consent was obtained at ICU admission, or if the patient was too severely ill, the consent was obtained as soon as possible. If the patient died before consent could be obtained, consent was presumed. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were followed []. The study was registered on ClinicalTrials.gov Identifier: NCT04974775.

: Not applicable.

: All authors declare no competing, financial, or other interests.

Document is current

Any future updates will be listed below